Colorectal cancer (CRC) is a feared complication of chronic ulcerative colitis (UC). Annual endoscopic surveillance is recommended for the detection of early neoplasia. 5-Aminosalicylates (5-ASAs) may prevent some UC-associated CRC. Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and ineffi cient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs.
INTRODUCTION
Colorectal cancer (CRC) is a feared complication of chronic ulcerative colitis (UC). Th e cumulative incidence of CRC aft er 30 years of UC is believed to be as high as 21.5 % (1) . Gastroenterology societies recommend regular colonoscopic surveillance with random biopsies every 1 -2 years aft er 8 -10 years of pancolitis (2 -4) . Colectomy is performed if highgrade dysplasia or cancer is identifi ed and confi rmed, and is oft en recommended for confi rmed low-grade dysplasia (5) .
Th e eff ectiveness of this cancer prevention strategy is limited by sampling error, variation in histologic interpretation, and poor adherence. 5-ASA medications are used to treat chronic ulcerative colitis, and have been associated with decreased risk of the development of colorectal cancer (6 -9) . However, not all epidemiological studies have found this association (10, 11) . A meta-analysis of the existing studies found that the usage of 5-ASA was associated with a net reduction of 49 % in CRC incidence in chronic ulcerative colitis (12) . It is believed that
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UC Surveillance in Setting of 5-ASA 5-ASA medications are plausible chemopreventive agents, as they have been shown to produce activation of caspases and to induce apoptosis in cancer cells in vitro (13 -20) . In fact, in vivo studies in humans with colon cancer have shown that mesalamine enemas can induce apoptosis in colon tumors (21) . Th e usage of mesalamine also seems to decrease proliferation and increase the apoptosis rate in normal colonic mucosa (22) . Th ese results suggest that 5-ASA compounds could plausibly reduce the occurrence of dysplasia, or cause apoptosis and regression of pre-existing dysplasia.
As many patients with UC are prescribed 5-ASA for maintenance of remission, they may simultaneously benefi t from chemoprevention by 5-ASA for CRC. In that setting, annual colonoscopic surveillance may provide little incremental benefi t in terms of detecting neoplasia compared with less frequent surveillance, and the risks of the procedure may outweigh those benefi ts. Furthermore, the cost of annual surveillance might not be justifi ed by a very small incremental benefi t. None of the published decision analyses regarding prevention of CRC in UC have accounted for the eff ect of chemoprevention (23 -25) . We hypothesized that among patients receiving 5-ASA, the most cost-eff ective frequency of colonoscopic surveillance would be less oft en than annually. We developed a Markov model and performed a cost-eff ectiveness analysis to answer this question, and to determine which variables signifi cantly aff ect the ideal surveillance interval.
METHODS
Subjects
Th e hypothetical cohort consisted of 35-year-old men with a 10-year history of ulcerative pancolitis that is quiescent at the time of enrollment. Th e analysis followed the cohort until the age of 90 years or death, whichever occurred fi rst.
Model
Decision analysis was modeled by creating a Markov process with TreeAge Pro 2007 soft ware (TreeAge, Williamstown, MA). A Markov process is a mathematical simulation of hypothetical patients over time. Unlike decision trees, Markov processes are recursive, allowing movement back and forth between health states at the end of each 1-year cycle. A simplifi ed schematic representation of the model is shown in Figure 1 . Th e actual model contains thousands of nodes, accounting for the natural history of patients with quiescent UC, and the various strategies for CRC mortality prevention (5-ASA alone and surveillance in intervals of 1 -10 years with or without 5-ASA). Th e model includes risks of iatrogenic complications, undetected dysplasia or cancer, and false-positive results indicating neoplasia.
Natural history
Th e reference strategy was the natural history of UC without any 5-ASA or surveillance. Patients could have a severe fl are of disease requiring a total colectomy and ileal pouch -anal anastomosis (IPAA), develop dysplasia (although this would go undetected as they did not receive surveillance), and progress from dysplasia to cancer, which would be detected only when it became symptomatic. Th e prevalence of cancer 10 years aft er diagnosis of UC was based on a published meta-analysis (1) . Th e annual incidence of cancer thereaft er was assumed to be constant over time, and was based on the same meta-analysis. We assumed that there was no possibility of regressing from true dysplasia, and that there was no possibility of developing cancer without fi rst progressing through dysplasia; both assumptions bias the model in favor of surveillance. Localized or regional cancer was treated with total colectomy. Patients with regional cancer also received chemotherapy for 8 weeks.
Patients with metastatic cancer did not undergo surgery, but received four cycles of chemotherapy (26) . Patients could die from CRC, from a complication of surgery, from a colitis fl are, or of causes unrelated to colitis. Stage-specifi c CRC mortality rates were obtained from the Surveillance Epidemiology and End Results Registry (27) . Age-specifi c mortality rates in patients with UC from causes other than CRC or directly related to colitis were derived from empiric data (28, 29) .
Surveillance colonoscopy
We created 10 strategies of surveillance colonoscopy without 5-ASA, ranging from intervals of every 1 to 10 years. In each of these strategies, random mucosal biopsies were obtained in four quadrants every 10 centimeters, and submitted to pathology in four separate specimen containers. If dysplasia was diagnosed, patients underwent total colectomy with IPAA. If cancer was detected, therapy was guided by stage as in the natural history arm. Th e surveillance strategies incorporated false-negative and false-positive rates, as well as morbid and mortal complications of endoscopy. We assumed that cancers diagnosed by surveillance colonoscopy were asymptomatic and therefore less likely to be metastatic (30) .
5-ASA alone
In this strategy, patients received 2.4 g of Asacol per day for maintenance of UC remission, but did not undergo any surveillance. A previously published meta-analysis was updated to include two more recently published articles assessing the eff ect of 5-ASA on the risk of UC-associated CRC (10, 12, 31) . Using MIX 1.7 soft ware (32, 33) , the resulting random eff ects model provided a summary odds ratio of 0.57 (95 % confi dence interval 0.40, 0.81). Th e annual incidence risk ratio for 5-ASA was calibrated to this odds ratio aft er 10 years of follow-up in the model (20 years aft er UC diagnosis because the patients enter the model aft er a 10-year history of UC). We assumed that the protective eff ect of 5-ASA was equal for the rate of progression from no dysplasia to dysplasia and for the rate of progression from dysplasia to cancer. A sensitivity analysis was performed to determine whether the outcomes changed if the eff ect of 5-ASA was entirely in the fi rst transition or the second transition.
5-ASA plus surveillance colonoscopy
Th ere were 10 combination strategies of 5-ASA with colonoscopic surveillance, ranging from every 1 -10 years. Th ese patients had a decreased rate of developing dysplasia and cancer (as in the 5-ASA strategy), underwent colectomy with IPAA for dysplasia when detected by surveillance, and benefi ted from surveillance by detecting cancers at earlier stages (as in the surveillance strategies).
Transition rates
Transition rates between the health states were derived from the published literature ( 
Costs and utilities
Th e perspective was that of a third-party payer; therefore, modeled costs included direct healthcare costs, but not indirect healthcare costs (such as lost productivity costs for patients and their families), or direct non-healthcare costs (such as patient transportation costs) ( Table 1 ) (34) . Th e wholesale cost of Asacol, 2.4 g daily, was estimated by the average price off ered by eight online discount pharmacies (35) . Th e base case cost of chemotherapy was based on 5-fl urouracil, leucovorin and oxaliplatin given as the FOLFOX regimen; the upper limit added the cost of bevacizumab (26) . Discrete procedural and hospitalization costs were based on median national reimbursements from the Centers for Medicare and Medicaid Services for the year 2007. Listed costs for endoscopies include the cost of histopathologic processing and interpretation. Th e cost of diagnosing and staging symptomatic cancer included the cost of colonoscopy with biopsy, computed tomogram and laboratory tests. Th e costs of chronic care of UC, and complications of colonoscopy were derived from published estimates, adjusting for 3 % annual infl ation to the year 2007. If 95 % confi dence limits were not available, the upper and lower limits were set at 1 / 2 and two times the base case estimate of cost, respectively. Utilities are ratios refl ecting patient preferences for particular health states, ranging from 0 (death) to 1 (perfect health). Utilities were based on published empiric data for CRC and IPAA ( Table 1 ) . Th e utilities of UC on and off 5-ASA were estimated as weighted averages of the utility of UC in remission and an outpatient UC fl are, assuming the decrement of quality of life from a UC fl are lasting 10 weeks, and accounting for the annual likelihood of a symptomatic fl are on and off 5-ASA. Th e utility of an outpatient UC fl are was derived as described earlier (36) . Th e utility for UC in remission was determined empirically using the time trade-off method from n = 46 patients at the University of Michigan (median utility = 0.99, interquartile range = 0.91, 1.00). Th e Institutional Review Board of the University of Michigan approved that portion of the study. Subjects were deemed in remission if their Simple Clinical Colitis Index was less than 3 (37) . All costs and utilities were discounted at an annual rate of 3 % , with sensitivity analysis from 0 to 5 % .
Outcomes
Th e time horizon of the model was until age 90 years or death (whichever was earliest), and the outcomes were judged from the perspective of a third-party payer. Th e incremental costeff ectiveness ratio is defi ned as the diff erence in cost in dollars, divided by the diff erence in eff ectiveness in quality-adjusted life-years (QALYs) between competing strategies. Th e primary outcome was the ideal strategy in a patient already taking 5-ASA; we defi ned the ideal strategy as the one providing the most QALYs at a cost of no more than $ 100,000 per each additional QALY compared with the next most eff ective strategy (willingness to pay = $ 100,000 / QALY) (38) . Additional outcomes measured for each strategy included the lifetime risk of CRC, life expectancy, and the proportion undergoing colectomy for cancer, dysplasia, false-positive neoplasia, and fl are.
Sensitivity analyses
One-way sensitivity analyses were performed over the specifi ed ranges for each variable ( Table 1 ) , comparing all strategies simultaneously to determine which strategy was ideal. Th e relative eff ects of 5-ASA on the progression to dysplasia, and from dysplasia to cancer, were explored by attributing the incidence risk ratio of cancer entirely to the fi rst transition or the second.
Probabilistic Monte Carlo simulation was performed to simultaneously randomly vary each variable in the model for strategies with 5-ASA. Th e type of distribution used for each variable, their median and 95 % confi dence interval, are displayed in Table  1 . Beta distributions were used for probabilities and utilities.
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Mortality from colectomy performed for surveillance 1.9 % 0.5 -6.6 % (1.5 % ; 0.1 -5.9 % )
Morbid perioperative complication from colectomy. 
RESULTS
Natural history
Over their entire lifetimes, 30 % of patients not receiving 5-ASA or surveillance colonoscopy developed colorectal cancer ( Figure 2 ). In 23 % of patients, the cancer was found at an early enough stage that they underwent colectomy, and 7 % had distant metastatic CRC. An additional 7 % underwent colectomy for a severe fl are of UC ( Figure 3 ) . Th e average life expectancy was 71.4 years ( Figure 4 ). Patients experienced 20.07 QALYs in their remaining lives at a discounted lifetime cost of $ 71,000 ( Figure 5 ).
Lognormal distributions were used for relative risks and costs. Th e covariance structure was assumed to be symmetrical. Th e model was run with 1,000 independent simulations, and the proportion of simulations in which each strategy was ideal at any particular willingness to pay was calculated. As the strategies being compared are diff erent in frequency of surveillance rather than categorical diff erences, the data is presented as cumulative acceptability curves stacking more frequent intervals on less frequent intervals. Th e Monte Carlo simulations were also repeated with 1,000 simulations with the effi cacy of 5-ASA held constant at its most and least effi cacious chemoprevention. 
Surveillance colonoscopy alone
In the absence of 5-ASA, performing surveillance every 10 years decreased the lifetime risk of CRC to 19 % ( Figure 2 ). Shorter intervals between surveillance were associated with progressively lower risks of CRC, such that annual surveillance led to a lifetime risk of CRC of 3 % . Surveillance led to a higher incidence of colectomy, largely due to the detection of dysplasia, but also a small incidence attributable to false-positive fi ndings of neoplasia ( Figure 3 ). Twentynine percent of those undergoing annual surveillance eventually underwent colectomy due to dysplasia. Shorter intervals between surveillance led to substantial incremental improvements in life expectancy ( Figure 4 ). Despite the decrement in quality of life related to colectomy resulting from surveillance, this improvement in life expectancy led to substantial incremental benefi ts in QALYs ( Figure 5 ). Annual surveillance cost $ 69,100 per each additional QALY compared with surveillance every other year, an incremental q10  q9  q8  q7  q6  q5  q4  q3  q2  q1  q10  q9  q8  q7  q6  q5  q4  q3  q2 q10  q9  q8  q7  q6  q5  q4  q3  q2  q1  q10  q9  q8  q7  q6  q5  q4  q3  q2  q1 5ASA alone
5-ASA
No 5-ASA Figure 5 . Cost -QALY plot for patients without 5-ASA. The x axis displays average remaining quality-adjusted life-years (QALYs) for each of 11 strategies without 5-ASA. The y axis displays average lifetime costs accrued after age 35. Up until surveillance every 4 years, progressively shorter surveillance intervals dominate the longer intervals, meaning that they provide more QALYs at lower cost. Beginning with surveillance every 3 years, the incremental cost-effectiveness ratio is depicted by the slope of the line connecting two strategies (the extra cost per QALY gained). Annual surveillance is ideal because it provides the most QALYs at a cost that is less than the threshold of $ 100,000 per QALY. 
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cancer were reduced so that the lifetime risk of cancer in the natural history were 10 % (which calibrated to annual risk of 0.24 % in the model), then in the setting of 5-ASA, surveillance every 7 years would be ideal.
We assessed the robustness of the model to variations in the assumption of the mechanism of action of 5-ASA. In the base case, we had assumed that the eff ect of 5-ASA was equally cost-eff ectiveness ratio that falls below the $ 100,000 / QALY willingness-to-pay threshold.
5-ASA alone
5-ASA without any surveillance prevented 49 % of expected cancers ( Figure 2 ), a proportion equivalent to that prevented by surveillance every 6 -7 years without the use of 5-ASA. Life expectancy with 5-ASA alone was similar to that with surveillance every 5 -6 years in the absence of 5-ASA ( Figure 4 ) . Th e lifetime risk of colectomy for any indication was reduced to 19 % , the lowest of any strategy ( Figure 3 ).
Surveillance colonoscopy in the setting of 5-ASA
In the setting of a patient taking 5-ASA for maintenance of remission, performing surveillance colonoscopy every 10 years reduced the risk of cancer to 7 % , a risk similar to that of a patient not treated with 5-ASA who undergoes surveillance every other year ( Figure 2 ). Surveillance performed at progressively shorter intervals resulted in incremental reductions in risk of cancer of less than 1 % . Surveillance every 3 years while taking 5-ASA led to a slightly greater risk of cancer as annual surveillance in the absence of 5-ASA (3.9 vs. 3.4 % ). Regardless of the surveillance interval, all patients taking 5-ASA and undergoing surveillance had a lower risk of colectomy for any indication compared with the natural history arm ( Figure 3 ). 5-ASA plus surveillance every 4 -5 years led to a similar life expectancy as annual surveillance without 5-ASA ( Figure 4 ). Surveillance every 3 years cost $ 63,400 per additional QALY compared with surveillance every 4 years ( Figure 6 ). Because of the small incremental improvements in life expectancy, more frequent surveillance in the setting of 5-ASA may be construed as too expensive. Surveillance every other year cost $ 147,500 per QALY gained compared with every 3 years, and annual surveillance cost nearly $ 1 million per QALY gained compared with surveillance every other year.
One-way sensitivity analyses
To assess the robustness of the model results, we varied each of the variables across their ranges listed in Table 1 , determining the ideal strategy in the setting of 5-ASA. Only alterations in the variables listed in Table 2 resulted in an ideal surveillance interval that diff ered from the base case of every 3 years. For instance, if the incidence of cancer were at its upper limit, then in the setting of a patient taking 5-ASA, surveillance every 2 years was ideal. Surveillance every 2 years was also ideal if the effi cacy of 5-ASA for preventing colorectal cancer were at its lower limit. In no scenario was annual surveillance ideal in the setting of 5-ASA. In contrast, if the quality of life with ileo-anal anastomosis were at its lower limit, then surveillance every 7 years was ideal. Similarly, if the specifi city of colonoscopy for neoplasia were at its lower limit (the false-positive rate was at its upper limit) then surveillance every 9 years was ideal.
Th e range identifi ed in the annual incidence of cancer, and used in Tables 1 and 2 was obtained from a published metaanalysis (1) . However, if the lower limit of the incidence of Figure 6 . Cost-QALY plot for patients taking 5-ASA. This plot is similar to Figure 5 , but displays the 11 strategies for patients taking 5-ASA for maintenance of remission. Surveillance every 10 years dominates no surveillance, but progressively shorter intervals incur additional costs. Annual surveillance is extremely expensive (nearly $ 1 million per QALY gained). Surveillance every 3 years is ideal in the setting of a patient taking 5-ASA, because the cost of surveillance every 2 years is greater than that of the threshold of $ 100,000 per QALY. Note that the label for strategies of surveillance every 6 to 10 years is condensed due to space limitations; in this range (as in the range of shorter intervals), progressively shorter intervals provide more QALYs. One-way sensitivity analyses were performed on each variable across their ranges listed in Table 1 , evaluating for changes in the ideal strategy in the setting of a patient receiving 5-ASA for maintenance therapy. Only those analyses that resulted in changes from the base case result of 5-ASA with surveillance every 3 years are presented. For instance, if the cost of colonoscopy were at its lowest value, then surveillance every 2 years was ideal, and if the cost were at its highest value, then surveillance every 4 years was ideal. In no case was annual surveillance ideal. 5-ASA, 5-aminosalicylate; IPAA, colectomy with ileal pouch -anal anastomosis.
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UC Surveillance in Setting of 5-ASA weighted on the progression from no dysplasia to dysplasia and from dysplasia to cancer. If the eff ect was entirely on the progression from dysplasia to cancer, then surveillance colonoscopy would needlessly direct some proportion of patients with dysplasia to colectomy who would not have needed colectomy to prevent cancer. We found that in such a scenario, surveillance every 4 years was ideal. Furthermore, varying the effi cacy of 5-ASA resulted in ideal surveillance intervals of 2 -7 years. If the eff ect of 5-ASA were entirely on the progression from no dysplasia to dysplasia with no eff ect on the progression to cancer, then the ideal surveillance interval was every 2 years. In that case, varying the effi cacy of 5-ASA resulted in ideal intervals of 2 -3 years.
Monte Carlo simulations
Th e robustness of the models with and without 5-ASA was further tested by 1,000 independent Monte Carlo simulations, which simultaneously randomly varies each variable in the model. At a willingness to pay $ 100,000 for each additional QALY gained, in the absence of 5-ASA, annual surveillance was ideal in 67 % of simulations, and surveillance every 2 years was ideal in 29 % of simulations. At a willingness to pay of $ 50,000 per QALY, the corresponding proportions were 31 and 57 % for annual and biennial surveillance, respectively. At a willingness -to-pay of $ 250,000 per QALY, annual surveillance was ideal in 97 % of simulations.
In the setting of a patient taking 5-ASA, a surveillance interval every 2 years or less oft en was ideal in 95 % of simulations, at a willingness -to-pay of $ 100,000 per QALY gained ( Figure 7 ).
An interval of every 3 years or less oft en was ideal in 65 % of simulations. At a willingness to pay of $ 50,000 / QALY, the corresponding proportions were 99 and 85 % , respectively. At a willingness to pay of $ 250,000 / QALY, the corresponding proportions were 78 and 32 % , respectively. If the effi cacy of 5-ASA were held constant at the upper limit of relative risk (0.78), then surveillance every 2 years or less oft en was ideal in 79 % of simulations at a willingness to pay of $ 100,000 per QALY (data not shown in fi gures). If the effi cacy of 5-ASA were held constant at the lower limit of relative risk (0.30), then at a willingnessto-pay of $ 100,000 per QALY, surveillance every 3 years or less oft en was ideal in 94 % of simulations, and surveillance every 4 years or less oft en was ideal in 80 % of simulations (data not shown in fi gures).
DISCUSSION
We systematically reviewed the literature and performed a cost-eff ectiveness analysis of surveillance intervals to decrease mortality from CRC in the setting of chronic UC. In the setting of a patient taking 5-ASA medication to maintain remission of symptoms, we found that the chemopreventive properties of the medication allows for less intensive surveillance. In the base case scenario, surveillance every 3 years appeared ideal, as more frequent surveillance may be prohibitively expensive compared with its tiny incremental benefi ts. Annual surveillance cost nearly $ 1 million for each additional QALY compared with surveillance every other year, an order of magnitude greater than any accepted threshold of willingnessto-pay (24) . One-way sensitivity analyses indicated multiple scenarios at the extremes where surveillance every 2 years was ideal, but no scenario in which annual surveillance would be considered cost-eff ective. Probabilistic Monte Carlo simulation demonstrated that at a willingness to pay of $ 100,000 per QALY, surveillance every 2 years or less oft en was ideal in 95 % of simulations. In the absence of 5-ASA, there is considerable uncertainty regarding the ideal surveillance interval; the currently accepted practice of annual surveillance was found to be ideal in only 67 % of simulations.
Th is study was limited by the available empiric data, particularly regarding the natural history of UC developing into CRC. We could not identify a large study of incidence of CRC in a cohort of patients receiving neither surveillance nor 5-ASA. Likewise, the eff ect of 5-ASA on carcinogenesis is inferred from epidemiologic studies and basic science studies, but is not proven from prospective randomized controlled studies in humans. Th e observed epidemiologic relationship may be due to unmeasured confounders such as patient adherence and health-seeking behaviors. Furthermore, the locus of eff ect of 5-ASA on carcinogenesis (whether solely on the development of dysplasia, solely on the progression from dysplasia to cancer, or both), is not known. As a result, published guidelines do not recommend 5-ASA for chemoprevention, and the practice is controversial (3, 39) . However, one-way sensitivity analyses across plausible ranges failed to identify annual surveillance as Each area between lines represents the proportion of 1,000 Monte Carlo simulations in which that strategy is ideal at a particular willingness to pay. As the strategies are different from each other in degree (frequency of surveillance), rather than category, the curves are stacked to present the cumulative acceptability. Any point on a curve represents the proportion of simulations in which surveillance at that frequency or less often is ideal at that willingness to pay. Note that surveillance every 9 years was never ideal in more than 0.5 % of simulations at any willingness to pay, and was omitted from the graph. Also note the x axis is on a logarithmic scale. Willingness to pay ($/QALY) 100,000 1,000,000
the ideal strategy, and in Monte Carlo simulations, annual surveillance was the ideal strategy in only 5 % of simulations at a willingness to pay of $ 100,000 per QALY. Strengths of the study include the systematic review for input variables, the use of results from meta-analyses for key inputs, the structured comparison of multiple potential strategies for multiple outcomes, and the robustness of the results to the sensitivity analyses. Given the potential limitations of the study, we prefer to conservatively interpret the results, erring on the side of fewer cancers (and of too frequent costly surveillance). Th erefore, until better empiric data are available, we would suggest surveillance every 2 years in patients taking 5-ASA, but less frequent surveillance may actually be ideal. 5-aminosalicylates are not the only potential chemopreventive medications for UC-associated CRC. Folate, ursodiol, non-steroidal anti-infl ammatory drugs, and statins may also be eff ective (40 -45) . Th e results of this model could be applied to these other pharmaceuticals by applying their particular cost, effi cacy, and adverse eff ect profi le. A key conclusion from this study is that effi cacious chemoprevention, particularly if effi cacious for the step from dysplasia to cancer, could decrease the burden of surveillance for patients and the healthcare system.
Previous decision analyses have examined surveillance for CRC associated with UC. Provenzale and others performed a cost-eff ectiveness analysis comparing surveillance at various intervals and doing nothing (24) . Th ey concluded that surveillance every 3 to 4 years was the optimal strategy, and that more frequent surveillance extended life expectancy, but at a prohibitively high incremental cost. Our analysis also found that more frequent surveillance extended life expectancy, but we included the costs of chronic care of UC to bias the model in favor of surveillance and away from chemoprevention. Because we included this additional real cost, we found that in the absence of 5-ASA, annual surveillance is the ideal strategy. Delc ò and Sonnenberg (23) compared biannual surveillance to doing nothing in a cost-benefi t analysis, and concluded that surveillance could be preferred if the cumulative incidence of CRC was greater than 27 % . Th at result is consistent with our analysis. Our study is diff erent from both of these previous decision analyses in that it incorporates a novel strategy of chemoprevention.
In summary, we found that chemoprevention of colorectal cancer is a promising strategy for the management of patients with chronic ulcerative colitis. Until better empiric data on the effi cacy of 5-ASA and natural history of UC is available, this analysis may help guide patients and their physicians in choosing an appropriate surveillance interval. As 5-ASA compounds are so safe, and any randomized controlled trial of surveillance interval would require a very large sample size and long follow-up, unfortunately additional empiric data are unlikely to be available any time soon. In the setting of a patient already taking 5-ASA for maintenance of remission, the current study suggests that surveillance colonoscopy might be deferred to at least every other year, particularly in patients who fi nd annual surveillance too burdensome. Annual surveillance likely provides very little incremental benefi t at very substantial incremental cost.
